

## **Biosynth strengthens peptide business with acquisition of Cambridge Research Biochemicals**

10 May 2023 | News

### **Addition of UK based peptide and antibody production facilities expands peptides and biologics business in UK and Europe**

Biosynth, a supplier of critical raw materials to the life science industry, has acquired Cambridge Research Biochemicals (CRB), a leading independent producer of custom-made peptide and antibody tools, based in the UK and supplying researchers in the pharmaceutical, life science and academic sectors.

CRB brings a wealth of expertise to Biosynth's peptide division, which has existing operations in the US and the Netherlands. This includes leading expertise in complex peptide chemistry and fluorescent dye labelling. CRB also brings additional custom antibody capacity in Europe, to support customers through the generation of novel, complex or unusual mono- and poly-clonal antibodies unavailable in catalogs.

Dr Urs Spitz, CEO and President of Biosynth, said, "Having a network of peptide sites at key locations, staffed by industry experts, allows us to best serve our customers throughout research and development and with the most complex and labelled peptides and high quality antibodies."

Emily Humphrys, Managing Director of Cambridge Research Biochemicals said, "As one of the longest established peptide companies, we have over 40 years of experience and are proud to have a strong track record for peptide and antibody excellence with our customers. We see great similarities in the approach that Biosynth already take in leading with science and customer focus."